Reta-Cagri · Triple Agonist + Amylin Combination
Pre-mixed research blend combining retatrutide (GLP-1/GIP/glucagon triple agonist) with cagrilintide (amylin analog). Quadruple-pathway metabolic research.
This blend combines retatrutide's triple agonism (GLP-1, GIP, glucagon) with cagrilintide's amylin receptor activity, creating a four-receptor pathway model. Research interest focuses on maximizing metabolic impact across satiety, energy expenditure, and hepatic fat pathways.
Store lyophilized at -20°C. Reconstitute with bacteriostatic water. Use within 28 days at 2–8°C.